2018
DOI: 10.1056/nejmoa1716197
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Single-dose baloxavir was without evident safety concerns, was superior to placebo in alleviating influenza symptoms, and was superior to both oseltamivir and placebo in reducing the viral load 1 day after initiation of the trial regimen in patients with uncomplicated influenza. Evidence for the development of decreased susceptibility to baloxavir after treatment was also observed. (Funded by Shionogi; JapicCTI number, 153090, and CAPSTONE-1 ClinicalTrials.gov number, NCT02954354 .).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

11
670
0
8

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 646 publications
(689 citation statements)
references
References 25 publications
11
670
0
8
Order By: Relevance
“…Single-dose baloxavir is superior to the placebo in alleviating influenza symptoms and to both oseltamivir and placebo in reducing the viral load 1 day after initiation in patients with uncomplicated influenza (Hayden, et al, 2018). The emergence of baloxavir-resistant mutants with PA/I38X substitutions occurred in 2.2% and 9.7% of baloxavir recipients in the phase 2 and phase 3 trials, respectively.…”
Section: J O U R N a L P R E -P R O O Fmentioning
confidence: 99%
“…Single-dose baloxavir is superior to the placebo in alleviating influenza symptoms and to both oseltamivir and placebo in reducing the viral load 1 day after initiation in patients with uncomplicated influenza (Hayden, et al, 2018). The emergence of baloxavir-resistant mutants with PA/I38X substitutions occurred in 2.2% and 9.7% of baloxavir recipients in the phase 2 and phase 3 trials, respectively.…”
Section: J O U R N a L P R E -P R O O Fmentioning
confidence: 99%
“…Actually, no better than oseltamivir (Tamiflu) in trials reported in the New England Journal of Medicine in September 1. Compared with a placebo, it reduced the duration of symptoms by just over a day in adults and by slightly longer (38.6 hours) in teenagers.…”
Section: Is It Any Good?mentioning
confidence: 99%
“…In a phase III study comparing a single dose of baloxavir 40–80 mg versus placebo or oseltamivir 75 mg twice daily (bd) in otherwise healthy influenza patients with uncomplicated influenza, baloxavir significantly reduced time to alleviation of symptoms by >24 h versus placebo and was comparable to oseltamivir. In addition, baloxavir significantly reduced viral titres versus placebo or oseltamivir from 1 day post dose …”
Section: Disclosure Statementmentioning
confidence: 93%